SCHEMBL4084162

SCHEMBL4084162

CCOC(=O)c1c(NC(=O)C2C(C)(C)C2(C)C)sc2c1CCC2

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.72
ALDH1A1 P00352 5/20 0.72
TSHR P16473 4/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
LMNA P02545 3/20 0.69
NPSR1 Q6W5P4 2/20 0.67
ATM Q13315 1/20 0.67
GAA P10253 2/20 0.66
ALOX15 P16050 1/20 0.66
HSD17B10 Q99714 1/20 0.66
CNR1 P21554 1/20 0.65
CNR2 P34972 1/20 0.65
HTT P42858 1/20 0.65
KDM4E B2RXH2 6/20 0.63
KMT2A Q03164 1/20 0.62
POLB P06746 2/20 0.61
TLR2 O60603 5/20 0.61
TP53 P04637 1/20 0.61
TLR1 Q15399 1/20 0.61
CTDSP1 Q9GZU7 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084306 0.98 CNR1 (0.69) MAPTALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL4090889 0.85 MAPT (0.59) MAPTALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL4080930 0.85 CNR2 (0.69) MAPTALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL5451004 0.84 MAPT (0.77) MAPTALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL4080512 0.84 ADORA1 (0.60) MAPTALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL13779376 0.84 ALDH1A1 (0.81) MAPTALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL4085865 0.83 KDM4E (0.68) MAPTALDH1A1TSHRSMN1; SMN2NPSR1
SCHEMBL4080594 0.82 ALDH1A1 (0.63) MAPTALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL8292134 0.82 MAPT (0.73) MAPTALDH1A1TSHRSMN1; SMN2LMNA
SCHEMBL3806687 0.82 MAPT (0.77) MAPTALDH1A1TSHRSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 MAPT 2527/4885ALDH1A1 1504/4885TSHR 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.